The dilemma of ICD implant testing

PACE - Pacing and Clinical Electrophysiology

Volumn 30, Issue 5, 2007, Pages 675-700

  Swerdlow, Charles D ^a,d   Russo, Andrea M ^b   Degroot, Paul J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDTRONIC INC   (United States)

^d NONE   (United States)

Author keywords

Defibrillation; Defibrillation threshold; Implantable cardioverter defibrillator

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZIMILIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; LIDOCAINE; POTASSIUM CHANNEL BLOCKING AGENT; SOTALOL;

BAYES THEOREM; CONVULSIVE THERAPY; DEFIBRILLATION; DEFIBRILLATOR; GENERAL ANESTHESIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LOCAL ANESTHESIA; MORTALITY; RECIPIENT; REVIEW; SUDDEN DEATH; SURGICAL MORTALITY; THROMBOEMBOLISM; TREATMENT FAILURE;

DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; EQUIPMENT SAFETY; HUMANS; PREDICTIVE VALUE OF TESTS; RISK REDUCTION BEHAVIOR; STATISTICS; TACHYCARDIA, VENTRICULAR; UNNECESSARY PROCEDURES; VENTRICULAR FIBRILLATION;

EID: 34247520975     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2007.00730.x     Document Type: Review

References (227)

1. Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol 2004 44 (1 88 91.
2. Neuzner J. Is DFT testing still mandatory? Herz 2005 30 (7 601.
3. Singer I, Lang D. Defibrillation threshold: Clinical utility and therapeutic implications. Pacing Clin Electrophysiol 1992 15 : 932 949.
4. Singer I, Lang D. The defibrillation threshold. In : Kroll M, Lehmann M (eds Implantable Cardioverter-Defibrillator Therapy: The Engineering-Clinical Interface. Norwell, MA, Kluwer Academic Publishers, 1996, pp. 89 130.
5. Gliner BE, Murakawa Y, Thakor NV. The defibrillation success rate versus energy relationship: Part I-Curve fitting and the most efficient defibrillation energy. Pacing Clin Electrophysiol 1990 13 (3 326 338.
6. Gliner BE, Murakawa Y, Thakor NV. The defibrillation success rate versus energy relationship: Part II-Estimation with the "bootstrap". Pacing Clin Electrophysiol 1990 13 (4 425 431.
7. Swerdlow C, Shehata M, Chen P. Using the upper limit of vulnerability to assess defibrillation efficacy at implantation of ICDs. Pacing and Clin Electrophsyiol 2007 : in press.
8. Mainigi SK, Callans DJ. How to manage the patient with a high defibrillation threshold. Heart Rhythm 2006 3 (4 492 495.
9. Natale A, Sra J, Axtell K, Akhtar M, Newby K, Kent V, Geiger MJ, et al. Undetected ventricular fibrillation in transvenous implantable cardioverter-defibrillators. Prospective comparison of different lead system-device combinations. Circulation 1996 93 (1 91 98.
10. Monahan K, Casavant D, Rasmussen C, Hallet N. Combined use of a true-bipolar sensing implantable cardioverter defibrillator in a patient having a prior implantable spinal cord stimulator for intractable pain. Pacing Clin Electrophysiol 1998 21 (12 2669 2672.
11. Schimpf R, Wolpert C, Herwig S, Schneider C, Esmailzadeh B, Luderitz B. Potential device interaction of a dual chamber implantable cardioverter defibrillator in a patient with continuous spinal cord stimulation. Europace 2003 5 (4 397 402.
12. Lawo T, Borggrefe M, Butter C, Hindricks G, Schmidinger H, Mika Y, Burkhoff D, et al. Electrical signals applied during the absolute refractory period: An investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol 20 2005 46 (12 2229 2236.
13. Glikson M, Trusty JM, Grice SK, Hayes DL, Hammill SC, Stanton MS. A stepwise testing protocol for modern implantable cardioverter-defibrillator systems to prevent pacemaker-implantable cardioverter- defibrillator interactions. Am J Cardiol 1999 83 (3 360 366.
14. Glikson M, Beeman AL, Luria DM, Hayes DL, Friedman PA. Impaired detection of ventricular tachyarrhythmias by a rate-smoothing algorithm in dual-chamber implantable defibrillators: Intradevice interactions. J Cardiovasc Electrophysiol 2002 13 (4 312 318.
15. Shivkumar K, Feliciano Z, Boyle NG, Wiener I. Intradevice interaction in a dual chamber implantable cardioverter defibrillator preventing ventricular tachyarrhythmia detection. J Cardiovasc Electrophysiol 2000 11 (11 1285 1288.
16. Ellenbogen KA, Wood MA, Stambler BS, Welch WJ, Damiano RJ. Measurement of ventricular electrogram amplitude during intraoperative induction of ventricular tachyarrhythmias. Am J Cardiol 1992 70 (11 1017 1022.
17. Swerdlow CD. Implantation of cardioverter defibrillators without induction of ventricular fibrillation. Circulation 2001 103 (17 2159 2164.
18. Swerdlow CD, Friedman PA. Advanced ICD troubleshooting: Part II. Pacing Clin Electrophysiol 2006 29 (1 70 96.
19. Dekker LR, Schrama TA, Steinmetz FH, Tukkie R. Undersensing of VF in a patient with optimal R wave sensing during sinus rhythm. Pacing Clin Electrophysiol 2004 27 (6 Pt 1 833 834.
20. Tchou PJ. Fixed tilt or programmable pulse widths: Are we creatures of habit? Heart Rhythm 2006 3 (5 542 543.
21. Swerdlow CD. ICD waveforms: What really matters? Heart Rhythm 2006 3 (9 1060 1062.
22. Kroll M, Swerdlow C. Optimal defibrillation waveforms for ICDs. J Interv Cardiol 2007 : in press.
23. Chen PS, Swerdlow CD, Hwang C, Karagueuzian HS. Current concepts of ventricular defibrillation. J Cardiovasc Electrophysiol 1998 9 (5 553 562.
24. Dillon SM, Kwaku KF. Progressive depolarization: A unified hypothesis for defibrillation and fibrillation induction by shocks. J Cardiovasc Electrophysiol 1998 9 (5 529 552.
25. Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm 2006 3 : 1100 1102.
26. Evans FG, Ideker RE, Gray RA. Effect of shock-induced changes in transmembrane potential on reentrant waves and outcome during cardioversion of isolated rabbit hearts. J Cardiovasc Electrophysiol 2002 13 (11 1118 1127.
27. Fast V. Cellular mechanisms of defibrillation. In : Zipes D, Jalife J (eds Cardiac Electrophysiology: From Cell to Bedside. 4th Ed. Philadelphia, Saunders, 2004, pp. 407 416.
28. Gray R. Global mechanisms of defibrillation. In : Zipes D, Jalife J (eds Cardiac Electrophysiology: From Cell to Bedside. Phiiladelphia, Saunders, 2004, pp. 417 425.
29. McDaniel WC, Schuder JC. The cardiac ventricular defibrillation threshold: Inherent limitations in its application and interpretation. Med Instrum 1987 21 (3 170 176.
30. Church T, Martinson M, Kallok M, Watson W. A model to evaluate alternative methods of defibrillation threshold determination. Pacing Clin Electrophysiol 1988 11 (11 Pt 2 2002 2007.
31. Davy JM, Fain ES, Dorian P, Winkle RA. The relationship between successful defibrillation and delivered energy in open-chest dogs: Reappraisal of the "defibrillation threshold" concept. Am Heart J 1987 113 : 77 84.
32. DeGroot PJ, Church TR, Mehra R, Martinson MS, Schaber DE. Derivation of a defibrillator implant criterion based on probability of successful defibrillation. Pacing Clin Electrophysiol 1997 20 (8 Pt 1 1924 1935.
33. Malkin RA, Souza JJ, Ideker RE. The ventricular defibrillation and upper limit of vulnerability dose-response curves. J Cardiovasc Electrophysiol 1997 8 (8 895 903.
34. Chen P-S, Shibata N, Dixon E, Martin R, Ideker R. Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability. Circulation 1986 73 : 1022 1028.
35. Chen P-S, Wolf P, Ideker R. Mechanism of cardiac defibrillation. Circulation 1991 84 : 914 919.
36. Day J, Doshi R, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P, Glatter K, et al. Most patients may safely undergo inductionless or limited shock testing at ICD implantation. Heart Rhythm 2005 2 : S232 Abstract.
37. Fabritz CL, Kirchhof PF, Behrens S, Zabel M, Franz MR. Myocardial vulnerability to T wave shocks: Relation to shock strength, shock coupling interval, and dispersion of ventricular repolarization. J Cardiovasc Electrophysiol 1996 7 (3 231 242.
38. Malkin R, Idriss S, Walker R, Ideker R. Effect of rapid pacing and T-wave scanning on the relation between the defibrillation and upper-limit-of- vulnerability dose-response curves. Circulation 1995 92 : 1291 1299.
39. Bessho R, Tanaka S. Measurement of the upper limit of vulnerability during defibrillator implantation can substitute defibrillation threshold measurement. Int J Artif Organs 1998 21 (3 151 160.
40. Birgersdotter-Green U, Undesser K, Fujimura O, Feld GK, Kass RM, Mandel WJ, Peter CT, et al. Correlation of acute and chronic defibrillation threshold with upper limit of vulnerability determined in normal sinus rhythm. J Interv Card Electrophysiol 1999 3 (2 155 161.
41. Chen PS, Feld GK, Kriett JM, Mower MM, Tarazi RY, Fleck RP, Swerdlow CD, et al. Relation between upper limit of vulnerability and defibrillation threshold in humans. Circulation 1993 88 (1 186 192.
42. Hui RC, Rosenthal L, Ramza B, Nsah E, Lawrence J, Tomaselli G, Berger R, et al. Relationship between the upper limit of vulnerability determined in normal sinus rhythm and the defibrillation threshold in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1998 21 (4 Pt 1 687 693.
43. Hwang C, Swerdlow CD, Kass RM, Gang ES, Mandel WJ, Peter CT, Chen PS. Upper limit of vulnerability reliably predicts the defibrillation threshold in humans. Circulation 1994 90 (5 2308 2314.
44. Kirilmaz A, Dokumaci B, Uzun M, Kilicaslan F, Dinckal MH, Yucel O, Karaca M. Detection of the defibrillation threshold using the upper limit of vulnerability following defibrillator implantation. Pacing Clin Electrophysiol 2005 28 (6 498 505.
45. Marchlinski FE, Flores B, Miller JM, Gottlieb CD, Hargrove WC. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator. Am J Cardiol 1988 62 (7 393 398.
46. Peleska B, Blazek Z. "Effect of serial inductivity in condenser defibrillators on the defibrillation threshold of the heart and proposals for a modification of the earlier prema type defibrillator.". Rozhl Chir 1963 42 : 704 711.
47. Rattes MF, Jones DL, Sharma AD, Klein GJ. Defibrillation threshold: A simple and quantitative estimate of the ability to defibrillate. Pacing Clin Electrophysiol 1987 10 (1 Pt 1 70 77.
48. Swerdlow CD, Davie S, Ahern T, Chen PS. Comparative reproducibility of defibrillation threshold and upper limit of vulnerability. Pacing Clin Electrophysiol 1996 19 (12 Pt 1 2103 2111.
49. Li H, Malkin RA. An approximate bayesian up-down method for estimating a percentage point on a dose-response curve. J Appl Stat 2000 27 (5 579 587.
50. Shorofsky SR, Peters RW, Rashba EJ, Gold MR. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol 2004 27 (2 218 220.
51. Annamraju S, Lieberman R, Meissner M, DeGroot P, Hill M. ICD defibrillation threshold determination via single VF induction. Pacing and Clin Electrophsyiol 2002 25 : 618 (abstract).
52. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, Payne J, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: Primary results from the Low Energy Safety Study (LESS). Circulation 2002 105 (17 2043 2048.
53. Higgins S, Mann D, Calkins H, Estes NA, Strickberger SA, Breiter D, Lang D, et al. One conversion of ventricular fibrillation is adequate for implantable cardioverter-defibrillator implant: An analysis from the Low Energy Safety Study (LESS). Heart Rhythm 2005 2 (2 117 122.
54. Gold MR, Breiter D, Leman R, Rashba EJ, Shorofsky SR, Hahn SJ. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol 2003 26 (1 Pt 2 483 486.
55. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: What it is and how to deal with it. Int J Epidemiol 2005 34 (1 215 220.
56. Fleminger S. Statistical notes. Regression towards the mean. British Med J 1994 309 (6953 539.
57. Stiratelli R, Laird N, Ware JH. Random-effects models for serial observations with binary response. Biometrics 1984 40 (4 961 971.
58. Breslow N, Clayton D. Breslow NE, Clayton DG : Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993 88 : 9 25.
59. Smits K, DeGroot P. A Bayesian approach to reduced implant testing of a ventricular defibrillator: A computer simulation. Europace 2004 6 (s1 S97 (Abstract).
60. Hall GH. The clinical application of Bayes' theorem. Lancet 1967 2 (7515 555 557.
61. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, et al. Defibrillation threshold testing: Is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm 2005 2 (5 456 461.
62. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004 110 (17 2591 2596.
63. Toal S, Harris L, Asta J, Hill A, Cameron D. Routine defibrillation threshold testing at implant in patients receiving defibrillators for primary prevention: Is this necessary?. Heart Rhythm 2006 3 (5 S157 S157 abstract.
64. DeGroot P, DeSouza CWW. Is testing defibrillation efficacy during defibrillator implant worth it? Pacing Clin Electrophysiol 1999 22 : 723 (abstract).
65. Sterns L, Morgan J, Wilkoff B, Molin F, Khalighi K, Lobban J, Ousdigian K, et al. Spontaneous shock efficacy following ICD implantation with an initial 10J termination of induced VF. Circulation 2005 112 : II 374. (abstract).
66. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 (3 225 237.
67. Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: How much is enough? J Cardiovasc Electrophysiol 2006 17 (2 140 145.
68. Poole J, Johnson G, Callans D, Raitt M, Yee R, Reddy R, Wilber D, et al. Analysis of implantable defibrillator shock electrograms in the Sudden Cardiac Death-Heart Failure Trial. Heart Rhythm 2004 1 : S178 (abstract).
69. Sweeney M, DeGroot P, Stark A, Otterness M, Buxton A, Wathen M, Investigators PRI. Relationship between defibrillation threshold, programmed energy and first shock efficacy for fast ventricular tachycardia and ventricular fibrillation in PainFREE Rx II. Circulation 2004 110 : II 503 (abstract).
70. Sterns L, Wilkoff B, Morgan J, et al. High energy first shock reduces the need for multiple shocks for polymorphic ventricular tachycardia or ventricular fibrillation. Heart Rhythm 2006 3 (5 S157 S158.
71. Kalus JS, White CM, Caron MF, Guertin D, McBride BF, Kluger J. The impact of catecholamines on defibrillation threshold in patients with implanted cardioverter defibrillators. Pacing Clin Electrophysiol 2005 28 (11 1147 1156.
72. Anastasiou-Nana MI, Tsagalou EP, Charitos C, Siafakas KX, Drakos S, Terrovitis JV, Ntalianis A, et al. Effects of transient myocardial ischemia on the ventricular defibrillation threshold. Pacing Clin Electrophysiol 2005 28 (2 97 101.
73. Ouyang P, Brinker JA, Bulkley BH, Jugdutt BI, Varghese PJ. Ischemic ventricular fibrillation: The importance of being spontaneous. Am J Cardiol 1981 48 (3 455 459.
74. Sims JJ, Miller AW, Ujhelyi MR. Regional hyperkalemia increases ventricular defibrillation energy requirements: Role of electrical heterogeneity in defibrillation. J Cardiovasc Electrophysiol 2000 11 (6 634 641.
75. Martin DJ, Chen PS, Hwang C, Gang ES, Mandel WJ, Peter CT, Swerdlow CD. Upper limit of vulnerability predicts chronic defibrillation threshold for transvenous implantable defibrillators. J Cardiovasc Electrophysiol 1997 8 (3 241 248.
76. Schauerte P, Diem B, Ziegert K, Franke A, Hanrath P, Stellbrink C. Influence of body position on defibrillation thresholds of nonthoracotomy implantable defibrillators: A prospective randomized evaluation. J Cardiovasc Electrophysiol 1998 9 (7 696 702.
77. Gradaus R, Bode-Schnurbus L, Weber M, Rotker J, Hammel D, Breithardt G, Bocker D. Effect of ventricular fibrillation duration on the defibrillation threshold in humans. Pacing Clin Electrophysiol 2002 25 (1 14 19.
78. Windecker S, Ideker RE, Plumb VJ, Kay GN, Walcott GP, Epstein AE. The influence of ventricular fibrillation duration on defibrillation efficacy using biphasic waveforms in humans. J Am Coll Cardiol 1999 33 (1 33 38.
79. Winkle RA, Mead RH, Ruder MA, Smith NA, Buch WS, Gaudiani VA. Effect of duration of ventricular fibrillation on defibrillation efficacy in humans. Circulation 1990 81 (5 1477 1481.
80. Venditti FJ Jr., John RM, Hull M, Tofler GH, Shahian DM, Martin DT. Circadian variation in defibrillation energy requirements. Circulation 1996 94 (7 1607 1612.
81. Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001 104 (7 796 801.
82. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005 Abstract 2005 111 (22 2898 2905.
83. Anderson KP. Sudden cardiac death unresponsive to implantable defibrillator therapy: An urgent target for clinicians, industry and government. J Interv Card Electrophysiol 2005 14 (2 71 78.
84. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators: The importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002 39 (8 1323 1328.
85. Pires LA, Hull ML, Nino CL, May LM, Ganji JR. Sudden death in recipients of transvenous implantable cardioverter defibrillator systems: Terminal events, predictors, and potential mechanisms. J Cardiovasc Electrophysiol 1999 10 (8 1049 1056.
86. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ. Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study. Circulation 1992 86 (4 1206 1216.
87. DeSouza C, Koehler J, DeGroot P. Failing defibrillator implant criterion on the initial attempt is a predictive factor for sudden cardiac death. Pacing Clin Electrophysiol 1998 21 : 801 (abstract).
88. Shukla HH, Flaker GC, Jayam V, Roberts D. High defibrillation thresholds in transvenous biphasic implantable defibrillators: Clinical predictors and prognostic implications. Pacing Clin Electrophysiol 2003 26 (1 Pt 1 44 48.
89. Wilkoff BL. Pacemaker and ICD malfunction-An incomplete picture. JAMA 2006 295 (16 1944 1946.
90. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: Results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006 48 (2 330 339.
91. Vollmann D, Luthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter defibrillator. Heart Rhythm 2005 3 : in press.
92. Gornick CC, Hauser RG, Almquist AK, Maron BJ. Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. Heart Rhythm 2005 2 (7 681 683.
93. Hauser RG, Hayes DL, Almquist AK, Epstein AE, Parsonnet V, Tyers GF, Vlay SC, et al. Unexpected ICD pulse generator failure due to electronic circuit damage caused by electrical overstress. Pacing Clin Electrophysiol 2001 24 (7 1046 1054.
94. Zipes DP, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. Circulation 1995 92 (1 59 65.
95. Sticherling C, Klingenheben T, Cameron D, Hohnloser SH. Worldwide clinical experience with a down-sized active can implantable cardioverter defibrillator in 162 consecutive patients. Worldwide 7221 ICD Investigators "In Process Citation". Pacing Clin Electrophysiol 1998 21 (9 1778 1783.
96. Brooks R, Garan H, Torchiana D, Vlahakes GJ, Jackson G, Newell J, McGovern BA, et al. Determinants of successful nonthoracotomy cardioverter-defibrillator implantation: Experience in 101 patients using two different lead systems. J Am Coll Cardiol 1993 22 (7 1835 1842.
97. Lehmann MH, Thomas A, Nabih M, Steinman RT, Fromm BS, Shah M, Norsted SW. Sudden death in recipients of first-generation implantable cardioverter defibrillators: Analysis of terminal events. Participating investigators. J Interv Cardiol 1994 7 (5 487 503.
98. Pinski SL, Vanerio G, Castle LW, Morant VA, Simmons TW, Trohman RG, Wilcoff BL, et al. Patients with a high defibrillation threshold: Clinical characteristics, management, and outcome. Am Heart J 1991 122 (1 Pt 1 89 95.
99. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004 15 (9 1002 1009.
100. Raviele A, Gasparini G. Italian multicenter clinical experience with endocardial defibrillation: Acute and long-term results in 307 patients. The Italian Endotak Investigator Group. Pacing Clin Electrophysiol 1995 18 (3 Pt 2 599 608.
101. Goyal R, Harvey M, Horwood L, Bogun F, Castellani M, Chan KK, Daoud E, et al. Incidence of lead system malfunction detected during implantable defibrillator generator replacement. Pacing Clin Electrophysiol 1996 19 (8 1143 1146.
102. Ellenbogen KA, Wood MA, Shepard RK, Clemo HF, Vaughn T, Holloman K, Dow M, et al. Detection and management of an implantable cardioverter defibrillator lead failure: Incidence and clinical implications. Journal of the American College of Cardiology 2003 41 (1 73 80.
103. Gold MR, Foster AH, Shorofsky SR. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol 1996 78 (5 540 543.
104. Gold MR, Foster AH, Shorofsky SR. Lead system optimization for transvenous defibrillation. Am J Cardiol 1997 80 (9 1163 1167.
105. Gold MR, Olsovsky MR, DeGroot PJ, Cuello C, Shorofsky SR. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol 2000 11 (1 25 29.
106. Schwartzman D, Callans DJ, Gottlieb CD, Heo J, Marchlinski FE. Early postoperative rise in defibrillation threshold in patients with nonthoracotomy defibrillation lead systems: Attenuation with biphasic shock waveforms. J Cardiovasc Electrophysiol 1996 7 (6 483 493.
107. Poole JE, Bardy GH, Dolack GL, Kudenchuk PJ, Anderson J, Johnson G. Serial defibrillation threshold measures in man: A prospective controlled study. J Cardiovasc Electrophysiol 1995 6 (1 19 25.
108. Venditti FJ Jr., Martin DT, Vassolas G, Bowen S. Rise in chronic defibrillation thresholds in nonthoracotomy implantable defibrillator. Circulation 1994 89 (1 216 223.
109. Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol 1997 30 (1 233 236.
110. Olsovsky MR, Pelini MA, Shorofsky SR, Gold MR. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol 1998 9 (3 240 244.
111. Tokano T, Pelosi F, Flemming M, Horwood L, Souza JJ, Zivin A, Knight BP, et al. Long-term evaluation of the ventricular defibrillation energy requirement. J Cardiovasc Electrophysiol 1998 9 (9 916 920.
112. Kroll M, Brewer J, Ellenbogen K. Upward DFT shift as a cause of sudden death. XII World Congress on Cardiac Pacing and Electrophysiology. Hong Kong, Medimond, 2003.
113. Brodsky CM, Chang F, Vlay SC. Multicenter evaluation of implantable cardioverter defibrillator testing after implant: The Post Implant Testing Study (PITS). Pacing Clin Electrophysiol 1999 22 (12 1769 1776.
114. Pelosi F Jr., Oral H, Kim MH, Sticherling C, Horwood L, Knight BP, Michaud GF, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000 11 (7 736 740.
115. Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: The optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006 114 (2 104 109.
116. Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998 31 (7 1672 1678.
117. Dorian P. Amiodarone and defibrillation thresholds: A clinical conundrum. J Cardiovasc Electrophysiol 2000 11 (7 741 743.
118. Kuhlkamp V, Mewis C, Suchalla R, Mermi J, Dornberger V, Seipel L. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol 1999 69 (3 271 279.
119. Shinlapawittayatorn K, Sungnoon R, Chattipakorn S, Chattipakorn N. Effects of sildenafil citrate on defibrillation efficacy. J Cardiovasc Electrophysiol 2006 17 (3 292 295.
120. Leitch JW, Yee R. Predictors of defibrillation efficacy in patients undergoing epicardial defibrillator implantation. The Multicenter Pacemaker-Cardioverter-Defibrillator (PCD) Investigators Group. Journal of the American College of Cardiology 1993 21 (7 1632 1637.
121. Horton RP, Canby RC, Roman CA, Hull ML, Kaye SA, Jessen ME, Page RL. Determinants of nonthoracotomy biphasic defibrillation. Pacing Clin Electrophysiol 1997 20 (1 Pt 1 60 64.
122. Lubinski A, Lewicka-Nowak E, Zienciuk A, Krolak T, Kempa M, Pazdyga A, Swiatecka G, et al. Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators. Kardiologia Polska 2005 62 (4 317.
123. Khalighi K, Daly B, Leino EV, Shorofsky SR, Kavesh NG, Peters RW, Gold MR. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol 1997 79 (2 150 153.
124. Hodgson DM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol 2002 25 (4 Pt 1 408 413.
125. Chapman PD, Sagar KB, Wetherbee JN, Troup PJ. Relationship of left ventricular mass to defibrillation threshold for the implantable defibrillator: A combined clinical and animal study. Am Heart J 1987 114 (2 274 278.
126. Schwartzman D, Concato J, Ren JF, Callans DJ, Gottlieb CD, Preminger MW, Marchlinski FE. Factors associated with successful implantation of nonthoracotomy defibrillation lead systems. Am Heart J 1996 131 (6 1127 1136.
127. Jastrzebski M, Czarnecka D, Bacior B, Petkow-Dimitrow P, Wilczek R, Kawecka-Jaszcz K. "Massive myocardial hypertrophy in hypertrophic cardiomyopathy: A risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation.". Kardiol Pol 2005 63 (2 191 195 discussion 196.
128. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005 2 (8 814 819.
129. Sweeney MO, Natale A, Volosin KJ, Swerdlow CD, Baker JH, Degroot P. Prospective randomized comparison of 50%/50% versus 65%/65% tilt biphasic waveform on defibrillation in humans. Pacing Clin Electrophysiol 2001 24 (1 60 65.
130. Denman RA, Umesan C, Martin PT, Forbes RN, Kroll MW, Anskey EJ, Burnett HE. Benefit of millisecond waveform durations for patients with high defibrillation thresholds. Heart Rhythm 2006 3 (5 536 541.
131. Mouchawar G, Kroll M, Val-Mejias JE, Schwartzman D, McKenzie J, Fitzgerald D, Prater S, et al. ICD waveform optimization: A randomized, prospective, pair-sampled multicenter study. Pacing Clin Electrophysiol 2000 23 (11 Pt 2 1992 1995.
132. Natarajan S, Henthorn S, Burroughs J, Esberg D, Zweibel S, Ross T, Kroll M, et al. Fixed duration "tuned" defibrillation waveforms outperform fixed 50/50% tilt defibrillation waveforms: A randomized, prospective, pair-sampled multicenter study (in press 2007).
133. Keane D, Aweh N, Hynes B, Sheahan R, Cripps T, Bashir Y, Zaidi A, et al. Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. Pacing and Clinical Electorphysiol 2007 18 : in press.
134. Merkely B, Lubinski A, Kiss O, Horkay F, Lewicka-Nowak E, Kempa M, Szabolcs Z, et al. Shortening the second phase duration of biphasic shocks: Effects of class III antiarrhythmic drugs on defibrillation efficacy in humans. J Cardiovasc Electrophysiol 2001 12 (7 824 827.
135. Thammanomai A, Sweeney MO, Eisenberg SR. A comparison of the output characteristics of several implantable cardioverter-defibrillators. Heart Rhythm 2006 3 (9 1053 1059.
136. Tomassoni G, Newby K, Deshpande S, Axtell K, Sra J, Akhtar M, Natale A. Defibrillation efficacy of commercially available biphasic impulses in humans. Importance of negative-phase peak voltage. Circulation 1997 95 (7 1822 1826.
137. Kroll MW, Efimov IR, Tchou PJ. Present understanding of shock polarity for internal defibrillation: The obvious and non-obvious clinical implications. Pacing Clin Electrophysiol 2006 29 (8 885 891.
138. Huang J, KenKnight BH, Walcott GP, Rollins DL, Smith WM, Ideker RE. Effects of transvenous electrode polarity and waveform duration on the relationship between defibrillation threshold and upper limit of vulnerability. Circulation 1997 96 (4 1351 1359.
139. Keelan ET, Sra JS, Axtell K, Maglio C, Underwood RD, Desphande S, Biehl M, et al. The effect of polarity of the initial phase of a biphasic shock waveform on the defibrillation threshold of pectorally implanted defibrillators. Pacing Clin Electrophysiol 1997 20 (2 Pt 1 337 342.
140. Olsovsky MR, Shorofsky SR, Gold MR. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J Cardiovasc Electrophysiol 1998 9 (4 350 354.
141. Shorofsky SR, Gold MR. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol 1996 78 (3 313 316.
142. Narasimhan C, Panotopoulos PT, Deshpande S, Jazayeri MR, Dhala A, Blanck Z, Akhtar M, et al. Reversing the initial phase polarity in biphasic shocks: Is the polarity benefit reproducible? Pacing Clin Electrophysiol 1999 22 (1 Pt 1 60 64.
143. Tang AS, Hendry P, Goldstein W, Green MS, Luce M. Nonthoracotomy implantation of cardioverter defibrillators: Preliminary experience with a defibrillation lead placed at the right ventricular outflow tract. Pacing Clin Electrophysiol 1996 19 (6 960 964.
144. Winter J, Heil JE, Schumann C, Lin Y, Schannwell CM, Michel U, Schipke JD, et al. Effect of implantable cardioverter/defibrillator lead placement in the right ventricle on defibrillation energy requirements. A combined experimental and clinical study. Eur J Cardiothorac Surg 1998 14 (4 419 425.
145. Lubinski A, Lewicka-Nowak E, Zienciuk A, Krolak T, Kempa M, Pazdyga A, Raczak G, et al. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can. Kardiol Pol 2005 63 (3 234 241 discussion 242-233.
146. Gold M, Val-Mejias J, Leman R, Tummala R, Goyal S, Kluger J, Kroll M, et al. Effect of SVC Coil usage and SVC electrode spacing on defibrillation thresholds Circulation 2006 114 : abstract, in press.
147. Manz M, Jung W, Luderitz B. Interactions between drugs and devices: Experimental and clinical studies. Am Heart J 1994 127 (4 Pt 2 978 984.
148. Cesario D, Bhargava M, Valderrabano M, Fonarow GC, Wilkoff B, Shivkumar K. Azygos vein lead implantation: A novel adjunctive technique for implantable cardioverter defibrillator placement. J Cardiovasc Electrophysiol 2004 15 (7 780 783.
149. Flaker GC, Tummala R, Wilson J. Comparison of right- and left-sided pectoral implantation parameters with the Jewel active can cardiodefibrillator. The World Wide Jewel Investigators. Pacing Clin Electrophysiol 1998 21 (2 447 451.
150. Roberts PR, Allen S, Betts T, Morgan JM, Urban JF, Whitman T, Euler DE,
151. Kuhlkamp V, Dornberger V, Khalighi K, Mewis C, Suchalla R, Ziemer G, Seipel L. Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing Clin Electrophysiol 1998 21 (12 2596 2605.
152. Gradaus R, Block M, Seidl K, Brunn J, Isgro F, Hammel D, Hauer B, et al. Defibrillation efficacy comparing a subcutaneous array electrode versus an "active can" implantable cardioverter defibrillator and a subcutaneous array electrode in addition to an "active can" implantable cardioverter defibrillator: Results from active can versus array trials I and II. J Cardiovasc Electrophysiol 2001 12 (8 921 927.
153. Schuger C, Ellenbogen KA, Faddis M, Knight BP, Yong P, Sample R. Defibrillation energy requirements in an ICD population receiving cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2006 17 (3 247 250.
154. Mainigi SK, Cooper JM, Russo AM, Nayak HM, Lin D, Dixit S, Gerstenfeld EP et al. Elevated defibrillation thresholds in patients undergoing biventricular defibrillator implantation: Incidence and predictors. Heart Rhythm 2006 3 (9 1010 1016.
155. Goldschlager N, Epstein A, Friedman P, Gang E, Krol R, Olshansky B. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: A practical guide to patient treatment. Arch Intern Med 2001 161 (5 649 655.
156. Rajawat YS, Dias D, Gerstenfeld EP, Dixit S, Shah B, Russo AM, Marchlinski FEM. Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation. Current Cardiology Reports 2002 4 (5 434 440.
157. Jung W, Manz M, Luderitz B. Effects of antiarrhythmic drugs on defibrillation threshold in patients with the implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1992 15 (4 Pt 3 645 648.
158. Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature. Pacing Clin Electrophysiol 1988 11 (1 7 12.
159. Brode SE, Schwartzman D, Callans DJ, Gottlieb CD, Marchlinski FE. ICD-antiarrhythmic drug and ICD-pacemaker interactions. J Cardiovasc Electrophysiol 1997 8 (7 830 842.
160. Carnes CA, Mehdirad AA, Nelson SD. Drug and defibrillator interactions. Pharmacotherapy 1998 18 (3 516 525.
161. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997 337 (22 1576 1583.
162. Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992 70 (11 1023 1027.
163. Wood MA, Ellenbogen KA. Follow-up defibrillator testing for antiarrhythmic drugs: Probability and uncertainty. Circulation 2006 114 (2 98 100.
164. Topham SL, Cha YM, Peters BB, Chen PS. Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs. Circulation 1992 85 (3 1146 1151.
165. Peters RW, Gilbert TB, Johns-Walton S, Gold MR. Lidocaine-related increase in defibrillation threshold. Anesth Analg 1997 85 (2 299 300.
166. Woosley RL, Echt DS, Roden DM. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol 1986 57 (3 25B 33B.
167. Dorian P, Newman D, Sheahan R, Tang A, Green M, Mitchell J. d-Sotalol decreases defibrillation energy requirements in humans: A novel indication for drug therapy. J Cardiovasc Electrophysiol 1996 7 (10 952 961.
168. Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004 43 (1 39 43.
169. Moerman A, Herregods L, Tavernier R, Jordaens L, Struys M, Rolly G. Influence of anaesthesia on defibrillation threshold. Anaesthesia 1998 53 (12 1156 1159.
170. Weinbroum AA, Glick A, Copperman Y, Yashar T, Rudick V, Flaishon R. H. Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: First report in humans. Anesth Analg 2002 95 (5 1147 1153, table of contents.
171. Helmers JH, Kraaijenhagen RJ, Leeuwen L, Zuurmond WW. Reduction of pain on injection caused by propofol. Can J Anaesth 1990 37 (2 267 268.
172. Lipscomb KJ, Linker NJ, Fitzpatrick AP. Subpectoral implantation of a cardioverter defibrillator under local anaesthesia. Heart 1998 79 (3 253 255.
173. Melichercik J, Goepfrich M, Breidenbach T, Von Hodenberg E. Rise of defibrillation energy requirement under carvedilol therapy. Pacing Clin Electrophysiol 2001 24 (9 Pt 1 1417 1419.
174. Kamochi H, Yamanouchi Y, Saku K. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on ventricular defibrillation threshold. Pacing Clin Electrophysiol 2006 29 (7 747 752.
175. Jones DL, Kim YH, Natale A, Klein GJ, Varin F. Bretylium decreases and verapamil increases defibrillation threshold in pigs. Pacing Clin Electrophysiol 1994 17 (8 1380 1390.
176. Jones DL, Klein GJ, Guiraudon GM, Yee R, Brown JE, Sharma AD. Effects of lidocaine and verapamil on defibrillation in humans. J Electrocardiol 1991 24 (4 299 305.
177. Lickfett L, Wolpert C, Jung W, Spehl S, Pizzulli L, Esmailzadeh B, Luderitz B. Inappropriate implantable defibrillator discharge caused by a retained pacemaker lead fragment. J Interv Card Electrophysiol 1999 3 (2 163 167.
178. Cohen TJ, Lowenkron DD. The effects of pneumothorax on defibrillation thresholds during pectoral implantation of an active can implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1998 21 (2 468 470.
179. Winter J, Zimmermann N, Lidolt H, Dees H, Perings C, Vester EG, Poll L, et al. Optimal method to achieve consistently low defibrillation energy requirements. Am J Cardiol 2000 86 (9A 71K 75K.
180. Swerdlow C, Shivkumar K, Zhang J. Determination of the upper limit of vulnerability using implantable cardioverter-defibrillator electrograms. Circulation 2003 107 (24 3028 3033.
181. Swerdlow C, Martin D, Kass R, Davie S, Mandel W, Gang E, Chen P. The zone of vulnerability to T-wave shocks in humans. J Cardiovasc Electrophysiol 1997 8 : 145 154.
182. Swerdlow C, Ahern T, Kass R, Davie S, Mandel W, Chen P-S. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter defibrillators. J Am Coll Cardiol 1996 27 : 1112 1117.
183. Swerdlow C, Peter C, Hwang C, Kass R, Mandel W, Gang E, Chen P. Programming of implantable defibrillators based on the upper limit of vulnerability rather than the defibrillation threshold. Circulation 1997 95 : 1497 1504.
184. Swerdlow C, Ahern T, Chen P-S. Comparative reproducibility of defibrillation threshold and upper limit of vulnerability. Pacing Clin Electrophysiol 1996 19 : 2103 2111.
185. Swerdlow CD, Kass RM, O'Connor ME, Chen PS. Effect of shock waveform on relationship between upper limit of vulnerability and defibrillation threshold. J Cardiovasc Electrophysiol 1998 9 (4 339 349.
186. Singer I, van der Laken J, Edmonds HL Jr., Slater AD, Austin E, Shields CB, Kupersmith J. Is defibrillation testing safe? Pacing Clin Electrophysiol 1991 14 (11 Pt 2 1899 1904.
187. de Vries JW, Bakker PF, Visser GH, Diephuis JC, van Huffelen AC. Changes in cerebral oxygen uptake and cerebral electrical activity during defibrillation threshold testing. Anesth Analg 1998 87 (1 16 20.
188. Singer I, Edmonds H Jr. Changes in cerebral perfusion during third-generation implantable cardioverter defibrillator testing. Am Heart J 1994 127 (4 Pt 2 1052 1057.
189. Vriens EM, Bakker PF, Vries JW, Wieneke GH, Van Huffelen AC. The impact of repeated short episodes of circulatory arrest on cerebral function. Reassuring electroencephalographic (EEG) findings during defibrillation threshold testing at defibrillator implantation. Electroencephalogr Clin Neurophysiol 1996 98 (4 236 242.
190. Schluter T, Baum H, Plewan A, Neumeier D. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. Clin Chem 2001 47 (3 459 463.
191. Hasdemir C, Shah N, Rao AP, Acosta H, Matsudaira K, Reynolds D, Beckman K. Effect of out-of-hospital implantable-cardioverter-defibrillator shocks on cardiac troponin I levels. Circulation 2000 : II 622.
192. McPherson CA, Blendea D. Clinical significance of elevated serum Troponin-T after implantable cardioverter-defibrillator discharges. Chest. October 1, 2003 2003 124 (4 151S-c 152S-c.
193. Frame R, Brodman R, Furman S, Kim SG, Rot J, Ferrick K, Hollinger I, et al. Clinical evaluation of the safety of repetitive intraoperative defibrillation threshold testing. Pacing Clin Electrophysiol 1992 15 (6 870 877.
194. Frame R, Brodman R, Gross J, Hollinger I, Fisher JD, Kim SG, Ferrick K, et al. Initial experience with transvenous implantable cardioverter defibrillator lead systems: Operative morbidity and mortality. Pacing Clin Electrophysiol 1993 16 (1 Pt 2 149 152.
195. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005 28 (9 926 932.
196. Atunes M, Spotnitz H, Livelli F, Steinberg J, Bigger J. Effect of electrophysiological testing on ejection fraction during cardioverter/ defibrillator implantation. Annals of Thoracic Surgery 1988 45 (3 315 318.
197. Meesman M. Factors associated with implantation-related complications. Pacing Clin Electrophysiol 1992 15 : 649 653.
198. Vlay SC. Defibrillation threshold testing: Necessary but evil? Am Heart J 1989 117 (2 499 504.
199. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A, Knight BP, et al. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998 9 (8 791 797.
200. Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, Tassani P. Hemodynamic deterioration during ICD implant: Predictors of high-risk patients. Am Heart J 1994 127 (4 Pt 2 1064 1067.
201. Spotnitz HM. Does ventricular fibrillation cause myocardial stunning during defibrillator implantation? J Card Surg 1993 8 (2 Suppl 249 256.
202. Antunes ML, Spotnitz HM, Livelli FD Jr., Steinberg JS, Bigger JT, Jr., Effect of electrophysiological testing on ejection fraction during cardioverter/defibrillator implantation. Ann Thorac Surg 1988 45 (3 315 318.
203. Stoddard MF, Redd RR, Buckingham TA, McBride LR, Labovitz AJ. Effects of electrophysiologic testing of the automatic implantable cardioverter- defibrillator on left ventricular systolic function and diastolic filling. Am Heart J 1991 122 (3 Pt 1 714 719.
204. Benedini G, Marchini A, Curnis A, Bianchetti F, Gardini A, Pinetti P, Zanelli E. Implantable defibrillation and thromboembolic events. Pacing Clin Electrophysiol 1995 18 (1 Pt 2 199 202.
205. Bangalore S, Petre L, Herweg B, Sichrovsky T, Vragel S, Steinberg JS, Chaudhry FA. Cardioversion in patients with left ventricular thrombus is not associated with increased thromboembolic risk. J Am Soc Echocardiogr 2006 19 (4 438 440.
206. Gasparini M, Galimberti P, Regoli F, Ceriotti C, Bonadies M. Delayed defibrillation testing in patients implanted with biventricular ICD (CRT-D): A reliable and safe approach. J Cardiovasc Electrophysiol 2005 16 (12 1279 1283.
207. Day J, Freedman R, Zubair I, Iskos D, Putz E, Compton S, Li C, et al. Most patients may safely undergo inductionless ICD implants. Circulation 2003 108 : IV-324 (abstract).
208. Riesgo MJ. "Anesthesia for the implantation of automatic defibrillators". Rev Esp Anestesiol Reanim 1999 46 (1 49.
209. Engelbrecht K. "Anesthesia in patients with pacemakers and automatic implanted defibrillators". Anaesthesist 1997 46 (12 1117 1128.
210. Stojeba N, Steib A, Fournier S, Loewenthal A, Chauvin M. "Anesthesia and implantable automatic defibrillator". Ann Fr Anesth Reanim 1996 15 (3 295 303.
211. Manolis AS, Maounis T, Vassilikos V, Chiladakis J, Cokkinos DV. Electrophysiologist-implanted transvenous cardioverter defibrillators using local versus general anesthesia. Pacing Clin Electrophysiol 2000 23 (1 96 105.
212. Pacifico A, Cedillo-Salazar FR, Nasir N Jr., Doyle TK, Henry PD. Conscious sedation with combined hypnotic agents for implantation of implantable cardioverter-defibrillators. J Am Coll Cardiol 1997 30 (3 769 773.
213. Knight BP, Pelosi F, Flemming M, Morady F, Strickberger SA. Effect of general anesthesia on the defibrillation energy requirement in patients undergoing defibrillator implantation. J Interv Card Electrophysiol 1999 3 (4 325 328.
214. Natale A, Kearney MM, Brandon MJ, Kent V, Wase A, Newby KH, Pisano E, et al. Safety of nurse-administered deep sedation for defibrillator implantation in the electrophysiology laboratory. J Cardiovasc Electrophysiol 1996 7 (4 301 306.
215. Vernooy K, Sicouri S, Dumaine R, Hong K, Oliva A, Burashnikov E, Timmermans C, et al. Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm 2006 3 (9 1074 1078.
216. Wilde AA, Langendijk PN. Brugada syndrome and the use of anesthetics. Heart Rhythm 2006 3 (9 1079 1081.
217. Neuzner J, Liebrich A, Jung J, Himmrich E, Pitschner HF, Winter J, Vester EG, et al. Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: Results of the prospective, randomized, multicenter Low-Energy Endotak Trial. Am J Cardiol 1999 83 (5B 34D 39D.
218. Pires LA, Lehmann MH, Steinman RT, et al. Sudden death in implantable cardioverter-defibrillator recipients: Clinical context, arrhythmic events and device responses. J Am Coll Cardiol 1999 33 (1 24 32.
219. Al-Khatib SM, Lucas FL, Jollis JG, Malenka DJ, Wennberg DE. The Relation Between Patients' Outcomes and the Volume of Cardioverter-Defibrillator Implantation Procedures Performed by Physicians Treating Medicare Beneficiaries. J Am Coll Cardiol 2005 46 (8 1536 1540.
220. Curtis AB, Ellenbogen KA, Hammill SC, Hayes DL, Reynolds DW, Wilber DJ, Cain ME. Clinical competency statement: Training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. Heart Rhythm 2004 1 (3 371 375.
221. Delvecchio A, Trivedi HA, Fisher JD, Kim SG, Ferrick KJ, Gross JN, Palma EC. Value of pre-hospital discharge defibrillation testing in recipients of implanted cardioverter defibrillators. Pacing Clin Electrophysiol 2005 28 Suppl 1 : S260 262.
222. Buob A, Siaplaouras S, Tscholl D, Schafers HJ, Bohm M, Jung J. Clinical value of routine predischarge testing after ICD-implantation. Europace 2004 6 (2 159 164.
223. Goldberger JJ, Horvath G, Inbar S, Kadish AH. Utility of predischarge and one-month transvenous implantable defibrillator tests. Am J Cardiol 1997 79 (6 822 826.
224. Higgins SL, Rich DH, Haygood JR, Barone J, Greer SL, Meyer DB. ICD restudy: Results and potential benefit from routine predischarge and 2-month evaluation. Pacing Clin Electrophysiol 1998 21 (2 410 417.
225. Glikson M, Luria D, Friedman PA, Trusty JM, Benderly M, Hammill SC, Stanton MS. Are routine arrhythmia inductions necessary in patients with pectoral implantable cardioverter defibrillators? J Cardiovasc Electrophysiol 2000 11 (2 127 135.
226. Wieckhorst A, Buchwald A, Unterberg C. On the necessity of the invasive predischarge test after implantation of a cardioverter-defibrillator. Am J Cardiol 1998 81 (7 933 935.
227. Swerdlow CD. Reappraisal of implant testing of implantable cardioverter defibrillators. J Am Coll Cardiol 2004 44 (1 92 94.